Navigation Links
Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
Date:5/1/2012

SUNNYVALE, Calif., May 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to present in the Emerging Companies Showcase at the New York Biotechnology Association's 21st Annual Meeting on May 2nd, 2012 in New York City at the Marriott Marquis Hotel. Mr. Commissiong will be hosting individual investor meetings following the presentation.

EVENT INFORMATION AT A GLANCE:WHO:

Gerald Commissiong, President and Chief Executive OfficerWHEN:

May 2nd, 2012 @ 2:30pm in the Lyceum RoomWHERE:

Marriott Marquis Hotel, 1535 Broadway, New York City, NYLIVE WEBCAST:

http://www.onemedplace.comAbout MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease.  The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research and a secondary program funded by the Brewer Sports International developing new treatments for Traumatic Brain Injury. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line.
It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc. Amaran
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amarantus BioSciences Reports Addition of New Scientific Articles to MANF Publications List
2. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
3. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
7. Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
8. Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating!
9. Celling Biosciences Sponsors 7th Annual Stem Cell Summit
10. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
11. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... 10 a.m. (Eastern Time) on Thursday, April 23, 2015, from ... Investors and other interested parties may access ... Company,s website at www.jnj.com and clicking on the ... meeting will be made available a few hours after the ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... , March 26, 2015 "Whether it,s our ... one day." In a single sentence, ... scientific officer at Pfizer,s Centers for Therapeutic Innovation ... scientists fueling progress at America,s biopharmaceutical companies. ... side-by-side with academia, patient foundations and the National Institutes ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... publishes largest study comparing cancer risk of ezetimibe ... -BOSTON, March 25 A new study shows ... ezetimibe/simvastatin combination treatments, compared to cancer rates of ... conducted by Tufts Medical Center lipid and health ...
... N.J., March 25 DOR BioPharma, Inc. (OTC Bulletin ... company, announced today that it has entered into a ... with its clinical trials management partner, Numoda Corporation (Numoda). ... be completed in January 2010. This investment follows ...
Cached Medicine Technology:Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 3DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 4DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 5
(Date:3/28/2015)... One in three young athletes who undergo ... at the American Orthopaedic Society for Sports Medicine’s ( ... term success of surgery for patients aged 18 years ... 242 patients who underwent ACL reconstruction between 1993 and ... from North Sydney Orthopaedic and Sports Medicine Centre. “Of ...
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Andrew Hawley ... original 1960's Who psychedelic concert posters. The Who and the ... York on August 2, 1968. According to Hawley, “The Who ... many concert halls and college campuses. Perhaps the most famous ... with Jim Morrison and the Doors on August 2, 1968 ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Designers and ... new overlay entitled Scratches 5K from Pixel Film Studios. ... effects to any media inside Final Cut Pro X” ... Corporate saves time and is an effective tool for ... FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply drag ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... First Choice Emergency Room opened its new Summerwood ... W Lake Houston Pkwy, Houston, Texas and is open 24-7. ... to delivering the highest quality emergency medical care to my ... Choice Emergency Room Summerwood. , To celebrate the ... Creek High School at First Choice Emergency Room’s ribbon cutting ...
Breaking Medicine News(10 mins):Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... with rheumatoid arthritis (RA), the most common chronic ... individuals to experience depression. Although depression in primary ... examined whether rheumatologists and RA patients discuss depression ... the February issue of Arthritis Care & Research ...
... Key to Behavior Change & Decrease in ... Disparities in care of,diabetes patients in ... interventions, according to a new,study published in ... Rates of,glucose control testing among Latinos with ...
... Care and HealthEOS announced today that they have reached an agreement ... ... As a result of the settlement,agreement, WPS customers that use the ... facilities through the end of,2008. The services provided to these WPS ...
... Feb. 1 The Obesity Action,Coalition (OAC) is calling ... House Bill 282 (HB 282) that discriminates,against those affected ... The OAC strongly feels that HB 282 is outright ... often misguided attempts,proposed to address the obesity epidemic., ...
... Association (APHA) today released its annual congressional record,which measures ... to public health., APHA,s report was compiled by ... votes during the first session of the 110th,Congress in ... senators voted in support of APHA,s,position on all eight ...
... - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division ... retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein ... to severe plaque psoriasis following 12 weeks of treatment. ... greater in the ENBREL treated group compared to the ...
Cached Medicine News:Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Lumetra Program Improves Diabetes Care Among Latinos 2Health News:Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:APHA Scores Members of Congress on Public Health Voting Record 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
... a scope designed specifically to enable direct ... also suitable for pediatric applications as well. ... a mere 2.8mm across. As a result, ... accomplished with greater ease. And since this ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
... a double lumen tube made of silicone rubber ... ,Due to the characteristics of silicone rubber, Silbronco ... at insertion. Furthermore, the tube will not soften ... long term surgery., ,Silbronco is also especially ...
Medicine Products: